glp-1 shortage over FDA's compounded limits will have ripple effects throughout the retail industry GLP-1 Drugs Market Size to
Description
A recent study analyzed the circulating microbiome of patients with alcoholic hepatitis, and found a decrease in Bacteroidetes and an enrichment of Fusobacteria

By drug class, the long-acting GLP-1 agonists segment held a dominant position in the market with a 63% share in 2025

Saxenda is also licensed for some adolescents according to specific criteria in its Summary of Product Characteristics (SmPC)

Oral semaglutide has been found to improve fasting blood glucose levels in a trial conducted over a 12 week period with improved levels of triglycerides, very low-density lipoprotein (VLDL), low- density lipoprotein (LDL) and apolipoprotein B48 (ApoB48) and no change in high density lipoprotein (HDL) (61)

Timper K, Del Ro-Martn A, Cremer AL, Bremser S, Alber J, Giavalisco P, et al

Well cover side effects, results, and costs to help you decide which prescription might work best for your own stubborn weight loss
